PT  - JOURNAL ARTICLE
AU  - Cunningham, Muriel
ED  - Crowther, Mark
TI  - ANNEXA-A
DP  - 2015 Sep 10
TA  - MD Conference Express
PG  - 9--9
VI  - 15
IP  - 21
4099  - http://mdc.sagepub.com/content/15/21/9.1.short
4100  - http://mdc.sagepub.com/content/15/21/9.1.full
AB  - In part 2 of the phase 3 ANNEXA-A trial, older subjects receiving a steady dose of apixaban were randomized to receive a bolus plus an infusion of andexanet alfa or placebo in a 3:1 ratio. Andexanet significantly reduced anti-fXa activity, decreased free apixaban, and normalized anticoagulation parameters. It was well tolerated in all study participants.